Fragment-based covalent ligand discovery

por Lu, Wenchao, Kostic, Milka, Zhang, Tinghu, Che, Jianwei, Patricelli, Matthew P., Jones, Lyn H., Chouchani, Edward T., Gray, Nathanael S.
Publicado 2021

Correction: Fragment-based covalent ligand discovery

por Lu, Wenchao, Kostic, Milka, Zhang, Tinghu, Che, Jianwei, Patricelli, Matthew P., Jones, Lyn H., Chouchani, Edward T., Gray, Nathanael S.
Publicado 2021

Identification of a Tumor Specific, Active-Site Mutation in Casein Kinase 1α by Chemical Proteomics

por Okerberg, Eric S., Hainley, Anna, Brown, Heidi, Aban, Arwin, Alemayehu, Senait, Shih, Ann, Wu, Jane, Patricelli, Matthew P., Kozarich, John W., Nomanbhoy, Tyzoon, Rosenblum, Jonathan S.
Publicado 2016

Correction: Identification of a Tumor Specific, Active-Site Mutation in Casein Kinase 1α by Chemical Proteomics

por Okerberg, Eric S., Hainley, Anna, Brown, Heidi, Aban, Arwin, Alemayehu, Senait, Shih, Ann, Wu, Jane, Patricelli, Matthew P., Kozarich, John W., Nomanbhoy, Tyzoon, Rosenblum, Jonathan S.
Publicado 2017

Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2

por Deng, Xianming, Dzamko, Nicolas, Prescott, Alan, Davies, Paul, Liu, Qingsong, Yang, Qingkai, Lee, Jiing-Dwan, Patricelli, Matthew P., Nomanbhoy, Tyzoon K., Alessi, Dario R., Gray, Nathanael S.
Publicado 2011

Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)

por Tan, Li, Nomanbhoy, Tyzoon, Gurbani, Deepak, Patricelli, Matthew, Hunter, John, Geng, Jiefei, Herhaus, Lina, Zhang, Jianming, Pauls, Eduardo, Ham, Youngjin, Choi, Hwan Geun, Xie, Ting, Deng, Xianming, Buhrlage, Sara J., Sim, Taebo, Cohen, Philip, Sapkota, Gopal, Westover, Kenneth D., Gray, Nathanael S.
Publicado 2014